 |
PDBsum entry 2nq0
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
46:6477-6487
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
|
|
Y.Wu,
D.Bhattacharyya,
C.L.King,
I.Baskerville-Abraham,
S.H.Huh,
G.Boysen,
J.A.Swenberg,
B.Temple,
S.L.Campbell,
S.G.Chaney.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Proteins that discriminate between cisplatin-DNA adducts and oxaliplatin-DNA
adducts are thought to be responsible for the differences in tumor range,
toxicity, and mutagenicity of these two important chemotherapeutic agents.
However, the structural basis for differential protein recognition of these
adducts has not been determined and could be important for the design of more
effective platinum anticancer agents. We have determined high-resolution NMR
structures for cisplatin-GG and undamaged DNA dodecamers in the AGGC sequence
context and have compared these structures with the oxaliplatin-GG structure in
the same sequence context determined previously in our laboratory. This
structural study allows the first direct comparison of cisplatin-GG DNA and
oxaliplatin-GG DNA solution structures referenced to undamaged DNA in the same
sequence context. Non-hydrogen atom rmsds of 0.81 and 1.21 were determined for
the 15 lowest-energy structures for cisplatin-GG DNA and undamaged DNA,
respectively, indicating good structural convergence. The theoretical NOESY
spectra obtained by back-calculation from the final average structures showed
excellent agreement with the experimental data, indicating that the final
structures are consistent with the NMR data. Several significant conformational
differences were observed between the cisplatin-GG adduct and the oxaliplatin-GG
adduct, including buckle at the 5' G6.C19 base pair, opening at the 3' G7.C18
base pair, twist at the A5G6.T20C19 base pair step, slide, twist, and roll at
the G6G7.C19C18 base pair step, slide at the G7C8.C18G17 base pair step, G6G7
dihedral angle, and overall bend angle. We hypothesize that these conformational
differences may be related to the ability of various DNA repair proteins, DNA
binding proteins, and DNA polymerases to discriminate between cisplatin-GG and
oxaliplatin-GG adducts.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.M.Pizarro,
and
P.J.Sadler
(2009).
Unusual DNA binding modes for metal anticancer complexes.
|
| |
Biochimie,
91,
1198-1211.
|
 |
|
|
|
|
 |
A.Sharma,
A.Ramanjaneyulu,
R.Ray,
and
M.R.Rajeswari
(2009).
Involvement of high mobility group B proteins in cisplatin-induced cytotoxicity in squamous cell carcinoma of skin.
|
| |
DNA Cell Biol,
28,
311-318.
|
 |
|
|
|
|
 |
R.C.Todd,
and
S.J.Lippard
(2009).
Inhibition of transcription by platinum antitumor compounds.
|
| |
Metallomics,
1,
280-291.
|
 |
|
|
|
|
 |
S.Ramachandran,
B.R.Temple,
S.G.Chaney,
and
N.V.Dokholyan
(2009).
Structural basis for the sequence-dependent effects of platinum-DNA adducts.
|
| |
Nucleic Acids Res,
37,
2434-2448.
|
 |
|
|
|
|
 |
S.Téletchéa,
T.Skauge,
E.Sletten,
and
J.Kozelka
(2009).
Cisplatin adducts on a GGG sequence within a DNA duplex studied by NMR spectroscopy and molecular dynamics simulations.
|
| |
Chemistry,
15,
12320-12337.
|
 |
|
|
|
|
 |
J.Malina,
O.Novakova,
M.Vojtiskova,
G.Natile,
and
V.Brabec
(2007).
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
|
| |
Biophys J,
93,
3950-3962.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |